Mary Wilson
Well-known member
NOTE: Title above reached maximum letters allowed for NewTopic. Below is the entire Title.
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers ? Eight U.S. Locations, December 2020?March 2021
Early Release / March 29, 2021 / 70
DOI: http://dx.doi.org/10.15585/mmwr.mm7013e3external icon
Mark G. Thompson, PhD[SUP]1[/SUP]; Jefferey L. Burgess, MD[SUP]2[/SUP]; Allison L. Naleway, PhD[SUP]3[/SUP]; Harmony L. Tyner, MD[SUP]4[/SUP]; Sarang K. Yoon, DO[SUP]5[/SUP]; Jennifer Meece, PhD[SUP]6[/SUP]; Lauren E.W. Olsho, PhD[SUP]7[/SUP]; Alberto J. Caban-Martinez, DO[SUP]8[/SUP]; Ashley Fowlkes, ScD[SUP]1[/SUP]; Karen Lutrick, PhD[SUP]2[/SUP]; Jennifer L. Kuntz, PhD[SUP]3[/SUP]; Kayan Dunnigan, MPH[SUP]9[/SUP]; Marilyn J. Odean, MS[SUP]10[/SUP]; Kurt T. Hegmann, MD[SUP]5[/SUP]; Elisha Stefanski[SUP]6[/SUP]; Laura J. Edwards, MPH[SUP]7[/SUP]; Natasha Schaefer-Solle, PhD[SUP]8[/SUP]; Lauren Grant, MS[SUP]1[/SUP]; Katherine Ellingson, PhD[SUP]2[/SUP]; Holly C. Groom, MPH[SUP]3[/SUP]; Tnelda Zunie[SUP]9[/SUP]; Matthew S. Thiese, PhD[SUP]5[/SUP]; Lynn Ivacic[SUP]6[/SUP]; Meredith G. Wesley, MPH[SUP]7[/SUP]; Julie Mayo Lamberte, MSPH[SUP]1[/SUP]; Xiaoxiao Sun, PhD[SUP]2[/SUP]; Michael E. Smith[SUP]9[/SUP]; Andrew L. Phillips, MD[SUP]5[/SUP]; Kimberly D. Groover, PhD[SUP]7[/SUP]; Young M. Yoo, MSPH[SUP]1[/SUP]; Joe Gerald, MD[SUP]2[/SUP]; Rachel T. Brown, PhD[SUP]5[/SUP]; Meghan K. Herring, MPH[SUP]7[/SUP]; Gregory Joseph, MPH[SUP]1[/SUP]; Shawn Beitel, MSc[SUP]2[/SUP]; Tyler C. Morrill, MS[SUP]7[/SUP]; Josephine Mak, MPH[SUP]1[/SUP]; Patrick Rivers, MPP[SUP]2[/SUP]; Katherine M. Harris, PhD[SUP]7[/SUP]; Danielle R. Hunt, PhD[SUP]7[/SUP]; Melissa L. Arvay, PhD[SUP]1[/SUP]; Preeta Kutty, MD[SUP]1[/SUP]; Alicia M. Fry, MD[SUP]1[/SUP]; Manjusha Gaglani, MBBS[SUP]9[/SUP][SUP],11[/SUP]
Summary
What is already known about this topic?
Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials.
What is added by this report?
Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (?14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (?14 days after first dose but before second dose) was 80%.
What are the implications for public health practice?
Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_w
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers ? Eight U.S. Locations, December 2020?March 2021
Early Release / March 29, 2021 / 70
DOI: http://dx.doi.org/10.15585/mmwr.mm7013e3external icon
Mark G. Thompson, PhD[SUP]1[/SUP]; Jefferey L. Burgess, MD[SUP]2[/SUP]; Allison L. Naleway, PhD[SUP]3[/SUP]; Harmony L. Tyner, MD[SUP]4[/SUP]; Sarang K. Yoon, DO[SUP]5[/SUP]; Jennifer Meece, PhD[SUP]6[/SUP]; Lauren E.W. Olsho, PhD[SUP]7[/SUP]; Alberto J. Caban-Martinez, DO[SUP]8[/SUP]; Ashley Fowlkes, ScD[SUP]1[/SUP]; Karen Lutrick, PhD[SUP]2[/SUP]; Jennifer L. Kuntz, PhD[SUP]3[/SUP]; Kayan Dunnigan, MPH[SUP]9[/SUP]; Marilyn J. Odean, MS[SUP]10[/SUP]; Kurt T. Hegmann, MD[SUP]5[/SUP]; Elisha Stefanski[SUP]6[/SUP]; Laura J. Edwards, MPH[SUP]7[/SUP]; Natasha Schaefer-Solle, PhD[SUP]8[/SUP]; Lauren Grant, MS[SUP]1[/SUP]; Katherine Ellingson, PhD[SUP]2[/SUP]; Holly C. Groom, MPH[SUP]3[/SUP]; Tnelda Zunie[SUP]9[/SUP]; Matthew S. Thiese, PhD[SUP]5[/SUP]; Lynn Ivacic[SUP]6[/SUP]; Meredith G. Wesley, MPH[SUP]7[/SUP]; Julie Mayo Lamberte, MSPH[SUP]1[/SUP]; Xiaoxiao Sun, PhD[SUP]2[/SUP]; Michael E. Smith[SUP]9[/SUP]; Andrew L. Phillips, MD[SUP]5[/SUP]; Kimberly D. Groover, PhD[SUP]7[/SUP]; Young M. Yoo, MSPH[SUP]1[/SUP]; Joe Gerald, MD[SUP]2[/SUP]; Rachel T. Brown, PhD[SUP]5[/SUP]; Meghan K. Herring, MPH[SUP]7[/SUP]; Gregory Joseph, MPH[SUP]1[/SUP]; Shawn Beitel, MSc[SUP]2[/SUP]; Tyler C. Morrill, MS[SUP]7[/SUP]; Josephine Mak, MPH[SUP]1[/SUP]; Patrick Rivers, MPP[SUP]2[/SUP]; Katherine M. Harris, PhD[SUP]7[/SUP]; Danielle R. Hunt, PhD[SUP]7[/SUP]; Melissa L. Arvay, PhD[SUP]1[/SUP]; Preeta Kutty, MD[SUP]1[/SUP]; Alicia M. Fry, MD[SUP]1[/SUP]; Manjusha Gaglani, MBBS[SUP]9[/SUP][SUP],11[/SUP]
Summary
What is already known about this topic?
Messenger RNA (mRNA) COVID-19 vaccines have been shown to be effective in preventing symptomatic SARS-CoV-2 infection in randomized placebo-controlled Phase III trials.
What is added by this report?
Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (?14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (?14 days after first dose but before second dose) was 80%.
What are the implications for public health practice?
Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7013e3.htm?s_cid=mm7013e3_w